Compare PRZO & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRZO | SCNX |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | Israel | United States |
| Employees | N/A | 19 |
| Industry | | Other Pharmaceuticals |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6M | 19.0M |
| IPO Year | 2022 | N/A |
| Metric | PRZO | SCNX |
|---|---|---|
| Price | $0.53 | $0.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | ★ 5.8M | 335.1K |
| Earning Date | 03-26-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,097.38 |
| Revenue Next Year | N/A | $239.80 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $0.24 |
| 52 Week High | $2.15 | $2.60 |
| Indicator | PRZO | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 41.44 | 50.42 |
| Support Level | $0.45 | $0.38 |
| Resistance Level | $0.82 | $0.43 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 4.48 | 63.24 |
ParaZero Technologies Ltd operates as an aerospace defense company focused on the development of smart, autonomous solutions for the manned and unmanned aerial systems (UAS) industry. The Company develops, manufactures, markets, and sells counter-UAS net-launching platforms designed to protect against hostile drones in both battlefield and urban environments, precision aerial delivery systems for military applications, and smart, autonomous parachute safety systems designed to enable safe flight operations over populated areas and beyond visual line-of-sight. The Company sells its products internationally.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.